Zobrazeno 1 - 10
of 38
pro vyhledávání: '"Eleonora Pelle"'
Publikováno v:
Journal of Clinical Medicine, Vol 9, Iss 11, p 3655 (2020)
Treatment options for neuroendocrine tumors (NETs) and carcinomas (NECs) are expanding. Early-phase studies have shown preliminary evidence of the antitumor activity of alpha-emitting peptide receptor radionuclide therapy (PRRT), and novel radiopepti
Externí odkaz:
https://doaj.org/article/c69f14496ed949d68887414e541adf61
Publikováno v:
Cancer J
Conventionally, adoptive cell therapies have been developed and optimized using αβ T cells. However, the understudied and less abundant γδ T cells offer unique advantages to the immunotherapy field specially for therapies against solid tumors. Re
Autor:
Eleonora Pelle, Mauro Cives, Elliot Medina, Charlotte C. Mason, Sebastian A. Snedal, Xiomar E. Bustos-Perez, Leticia Tordesillas, Fontela Miguel Gomez, Rossetti Renata A. Marques, Gabriele Maiorano, Vince Luca, Patrick Hwu, Daniel Abate-Daga, Jonathan Strosberg
Publikováno v:
Endocrine Abstracts.
Publikováno v:
Endocrine Abstracts.
Publikováno v:
Endocrine Abstracts.
Publikováno v:
Endocrine Abstracts.
Autor:
Eleonora Pelle, Mauro Cives, Elliot Medina, Charlotte Mason, Sebastian Snedal, Xiomar Bustos Perez, Leticia Tordesillas, Miguel Gomez Fontela, Renata Rossetti, Gabriele Maiorano, Vincent Luca, Patrick Hwu, Daniel Abate-Daga, Jonathan Strosberg
Publikováno v:
Regular and Young Investigator Award Abstracts.
Publikováno v:
Journal of the National Comprehensive Cancer Network : JNCCN. 20(12)
von Hippel-Lindau (VHL) disease is a rare autosomal-dominant hereditary disease characterized by mutation of the VHL gene. This gene encodes for the VHL protein, which regulates the activity of HIF-α, a transcription factor involved in the cellular
Autor:
Satya Das, Taymeyah Al-Toubah, Ghassan El-Haddad, Eleonora Pelle, Mintallah Haider, Jonathan R. Strosberg
Publikováno v:
Endocr Relat Cancer
Peptide receptor radionuclide therapy (PRRT) using 177Lu-DOTATATE has been approved for the treatment of gastroenteropancreatic NETs. An understanding of benefits and risks is important for the appropriate implementation of this therapy. This review
Autor:
Taymeyah Al-Toubah, Panpan Zhang, Rachel S van Leeuwaarde, Wouter W. de Herder, J. Hernando, Martin Caplin, Jonathan R. Strosberg, Eleonora Pelle, Louis de Mestier, Wouter T Zandee, Mauro Cives, Angela Lamarca, Agnieszka Kolasińska-Ćwikła, Elettra Merola, Jarosław B. Ćwikła, Teresa Alonso Gordoa, Faidon Laskaratos
Publikováno v:
Oncologist
Oncologist, 26(4), 294-301. AlphaMed Press
Oncologist, 26(4), 294-301. AlphaMed Press
Background Long-acting somatostatin analogs (SSAs) are the primary first-line treatment of well-differentiated advanced gastroenteropancreatic neuroendocrine tumors (NETs), but data about their efficacy in pancreatic NETs (panNETs) with Ki-67 ≥10%